1. Bristol-myers Squibb Compnay (9 from 3,681 patents)

2. Merck + Co., Inc. (8 from 4,770 patents)

3. Janssen Pharmaceutica Nv (1 from 2,076 patents)

4. Solvias Ag (1 from 35 patents)

1. 12378246 - Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one

2. 9518058 - Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide

3. 9403821 - Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound

4. 9394322 - Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound

5. 9376458 - Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound

6. 9255113 - Methods for the Preparation of HIV attachment inhibitor piperazine prodrug compound

7. 9249168 - Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound

8. 9243010 - Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound

9. 8889869 - Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound

10. 7495123 - Process for the preparation of enantiomerically enriched beta amino acid derivatives

11. 7468459 - Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation

12. 6706885 - Process for preparing integrin antagonist intermediates

13. 6646130 - Process to chiral integrin antagonist beta-amino acid intermediate

14. 6423845 - Process and intermediates to a tetrahydro-[1,8]- Naphthyridine

15. 6407241 - Process and intermediates for the preparation of imidazolidinone &agr;v integrin antagonists